Preferential Initiation of Long|Acting Injectable Versus Oral HIV Pre ...

Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre ...

Abstract · 1, · 2]. · 3]. · 4], suggesting they would benefit from increased access to HIV pre-exposure prophylaxis (PrEP). · 5]—in part, due to ...

Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre ...

HIV prevention; pre-exposure prophylaxis; women who inject drugs; long-acting injectable cabotegravir. Received 24 April 2024; editorial ...

Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre ...

More recent injection drug use and number of sexual partners were associated with selecting CAB-LA (P < .05). Findings provide preliminary ...

Preference for injectable over oral HIV pre-exposure prophylaxis in ...

Among surveyed respondents, 75% (95%CI 65–83%) stated preference for LAI over oral PrEP; with no differences by sex, age, or sexual behavior (all P>0.05).

AIDS 2024: Studies show strong user preference for long-acting ...

Researchers there found similar key themes: patients preferred injectable CAB-LA over daily oral PrEP due to convenience, no pill burden and the ...

Dynamic choice HIV prevention with cabotegravir long-acting ...

The intervention provided person-centred choice of oral pre-exposure prophylaxis (PrEP) or post-exposure HIV prophylaxis (PEP) or cabotegravir ...

Full article: Perceptions of the attributes of new long-acting HIV pre ...

Long-acting PrEP technologies like the injectable long-acting cabotegravir (CAB-LA) and the monthly dapivirine vaginal ring (DVR) have recently become available ...

Exploring preferences and decision-making about long-acting ...

Intramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (i.e., LAI-PrEP) was approved by the U.S. FDA in 2021.

Preference for long-acting injectable for ART and PrEP among ...

Among those with HIV, 91.5% expressed a high preference for LAI-ART, with significantly higher preferences among participants with higher ...

Willingness to use and preferences for long‐acting injectable PrEP ...

Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in ...

Perspectives on long-acting formulations of pre-exposure ...

SI-PrEP, similar to those used for contraception, provides sufficient drug concentrations to prevent HIV for up to one year [18]. Pill-based ...

Predicted effects of the introduction of long-acting injectable ...

Pre-exposure prophylaxis (PrEP) has the potential to substantially reduce HIV incidence but studies done in the region on use of oral PrEP have ...

WHO recommends long-acting cabotegravir for HIV prevention

Together, these landmark studies found that use of CAB-LA resulted in a 79% relative reduction in HIV risk compared with oral PrEP, where ...

Clinical Guidance for PrEP | HIV Nexus - CDC

Assess ongoing chances of HIV exposure and prescribe daily oral PrEP within 8 weeks after the last CAB injection or other prevention methods if ...

Systematic review of the values and preferences regarding the use ...

Pre-exposure prophylaxis (PrEP) is an important HIV prevention option. Two randomized trials have provided efficacy evidence for long-acting ...

Safety and Efficacy of Long-Acting Injectable Agents for HIV-1

The efficacy of CAB-LA+RPV-LA was comparable with that of daily oral drugs at 48 and 96 weeks (1302/1424, 91.43% vs 915/993, 92.2%; RR 0.99, 95% ...

HIV pre-exposure prophylaxis - UpToDate

(See 'Determining preference for oral versus injectable therapy' above.) For most patients, we suggest once-daily TDF-FTC (Grade 2C). This is ...

Injectable PrEP Frequently Asked Questions - Clinical - California PTC

Available evidence suggests that seven days after the first CAB-LA injection would be the appropriate time to stop oral TDF-FTC or TAF-FTC. Additional ...

Potential effectiveness of long-acting injectable pre-exposure ...

Long-acting injectable PrEP has the potential to produce larger reductions in HIV transmission in MSM than oral PrEP.

Satisfaction and acceptability of cabotegravir long-acting injectable ...

Most participants (74% [n = 67]) receiving consecutive injections favored cabotegravir LA vs oral cabotegravir. Most participants were satisfied ...